CLDX
NASDAQ · Biotechnology
Celldex Therapeutics Inc
$29.04
-1.06 (-3.52%)
Financial Highlights (FY 2026)
Revenue
1.89M
Net Income
-315,514,071
Gross Margin
100.0%
Profit Margin
-16,748.0%
Rev Growth
-13.2%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 37.0% | 37.0% |
| Operating Margin | -18,599.8% | -16,739.8% | -1.1% | -1.0% |
| Profit Margin | -16,748.0% | -15,910.6% | -0.8% | -1.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.89M | 2.17M | 613.37M | 463.47M |
| Gross Profit | 1.89M | 2.17M | 226.87M | 171.43M |
| Operating Income | -350,992,178 | -363,806,242 | -6,648,390 | -4,566,228 |
| Net Income | -315,514,071 | -327,032,896 | -4,777,656 | -4,595,403 |
| Gross Margin | 100.0% | 100.0% | 37.0% | 37.0% |
| Operating Margin | -18,599.8% | -16,739.8% | -1.1% | -1.0% |
| Profit Margin | -16,748.0% | -15,910.6% | -0.8% | -1.0% |
| Rev Growth | -13.2% | -13.2% | +23.6% | +12.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 650.05M | 724.29M |
| Total Equity | — | — | 684.23M | 651.26M |
| D/E Ratio | — | — | 0.95 | 1.11 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -346,274,202 | -378,855,800 | -9,452,277 | -7,129,969 |
| Free Cash Flow | — | — | -4,482,621 | -2,547,498 |